Immunotherapy plus chemo shows promise against tough head and neck cancers
Disease control
Completed
This early-phase trial tested adding the immunotherapy drug pembrolizumab to standard chemoradiation for people with advanced head and neck cancer. 59 participants received the combination to see if it was safe and how well it worked. The goal was to improve tumor control without…
Phase: PHASE1 • Sponsor: Sanford Health • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC